Quarterly report pursuant to Section 13 or 15(d)

Strategic Alliances (Details)

v3.19.1
Strategic Alliances (Details) - USD ($)
1 Months Ended 3 Months Ended 18 Months Ended 51 Months Ended 94 Months Ended
Oct. 12, 2017
Sep. 30, 2018
Jul. 31, 2018
May 31, 2016
Jan. 31, 2015
Dec. 31, 2010
Mar. 31, 2019
Mar. 31, 2018
Mar. 31, 2019
Mar. 31, 2019
Sep. 30, 2018
Dec. 31, 2018
Mar. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Upfront payment from development and license agreement $ 6,000,000                        
Milestone revenue recognized                 $ 0        
Contract liability             $ 73,000,000.0   73,000,000.0 $ 73,000,000.0   $ 91,100,000  
Contract liabilities             65,288,000   65,288,000 65,288,000   63,503,000  
Contract liabilities             7,708,000   7,708,000 7,708,000   $ 27,566,000  
VFMCRP | Development and License Agreement                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
License revenue, initial payment       $ 50,000,000                  
VFMCRP | Regulatory Milestones                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Additional milestone payment     $ 2,000,000.0                    
Additional milestone payment to be received       35,000,000                  
VFMCRP | Launch and Sales-based Milestones                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Additional milestone payment to be received       195,000,000                  
VFMCRP | Exclusive Option                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Additional milestone payment to be received       $ 555,000,000                  
Pfizer | Collaborative Arrangement, Product                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Milestone revenue recognized                   0      
Additional milestone payment to be received         $ 275,000,000.0                
Non-refundable and non-creditable upfront payment         295,000,000.0                
Contract liability             65,700,000   65,700,000 65,700,000      
Contract liabilities             62,400,000   62,400,000 62,400,000      
Contract liabilities             3,400,000   $ 3,400,000 $ 3,400,000      
Tesaro                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Milestone revenue recognized             $ 0 $ 0          
Additional milestone payment           $ 85,000,000              
Upfront payment under license agreements           $ 6,000,000.0              
Milestone payment received                     $ 30,000,000    
Period from first commercial sale           12 years              
Written termination threshold           3 months              
Minimum | Pfizer | Collaborative Arrangement, Product                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Each milestone payment         20,000,000.0                
Maximum | Pfizer | Collaborative Arrangement, Product                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Each milestone payment         $ 90,000,000.0                
Pharmsynthez                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Ownership percentage, equity method             9.00%   9.00% 9.00%      
Phio Pharmaceuticals                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Maximum milestone payments to be received                         $ 50,000,000.0
Phase Two Initiation                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Upfront payment from development and license agreement   $ 6,000,000                      
Regulatory and Development                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Milestone payment from development and license agreement 31,000,000                        
Sales Revenue                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Milestone payment from development and license agreement $ 75,000,000